{"entity":{"id":"absk061","kind":"drug","name":"ABSK061","aka":[],"tldr":"ABSK061 is an experimental small-molecule drug from Abbisko Therapeutics in phase 2 trials for gastric & gastro-oesophageal junction cancer, bladder & urothelial cancer and non-small-cell lung cancer, aimed at HER2 and FGFR2.","summary":"ABSK061 is a small-molecule drug developed by Abbisko Therapeutics. Its targets are HER2 and FGFR2. ClinicalTrials.gov describes the intervention as: Participants with HER2-Gastric/Gastroesophageal Junction Cancer and fibroblast growth factor receptor 2( FGFR2 ) amplification and overexpression will receive a dose of ABSK061 + ABSK043 oral capsule in combination with CAPOX until disease. It is the investigational product in 1 recruiting or active industry-led phase 2 and phase 3 interventional cancer trial, in gastric & gastro-oesophageal junction cancer, bladder & urothelial cancer and non-small-cell lung cancer. The largest, NCT06632262, plans to enrol 202 participants with primary completion expected 2029-11-30. Status reflects the highest phase registered on ClinicalTrials.gov; no efficacy results are recorded here.","status":"phase-2","asOf":"2026-09-11","links":[{"label":"ClinicalTrials.gov: trials of ABSK061","url":"https://clinicaltrials.gov/search?intr=ABSK061"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["gastric","urothelial","nsclc"],"sections":[],"technologies":[],"targets":["her2","fgfr2"],"drugs":[],"companies":["abbisko"],"institutions":[],"pathways":[],"terms":[],"trials":["nct06632262"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor pipeline pages)","editedOn":"2026-09-11"},"modality":"small molecule (structure undisclosed or not yet in PubChem)","mechanism":"Small-molecule drug directed at HER2 and FGFR2, as stated in the ClinicalTrials.gov intervention record; the detailed mechanism is not stated.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/absk061/","neighbours":{"cancer":[{"id":"urothelial","kind":"cancer","name":"Bladder & urothelial cancer","route":"/cancers/urothelial/"},{"id":"gastric","kind":"cancer","name":"Gastric & gastro-oesophageal junction cancer","route":"/cancers/gastric/"},{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}],"target":[{"id":"fgfr2","kind":"target","name":"FGFR2","route":"/targets/fgfr2/"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/"}],"company":[{"id":"abbisko","kind":"company","name":"Abbisko Therapeutics","route":"/companies/abbisko/"}],"trial":[{"id":"nct06632262","kind":"trial","name":"A Phase 2 Clinical Study of ABSK061 and ABSK043","route":"/trials/nct06632262/"}]}}